SCHEMBL17737448

SCHEMBL17737448

COc1ccc(S(=O)(=O)Nc2cccc3cnccc23)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.62
▸ NFE2L2 Q16236 1/20 0.62
▸ IDO1 P14902 1/20 0.61
▸ ABCB1 P08183 1/20 0.55
▸ ABCC1 P33527 1/20 0.55
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ LMNA P02545 4/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.51
▸ CA12 O43570 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HCRTR1 O43613 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ CNR2 P34972 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ DDX3X O00571 1/20 0.49
▸ AGTR1 P30556 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737360 0.85 SLC40A1 (0.64) KEAP1NFE2L2IDO1LMNAALDH1A1
SCHEMBL17737442 0.84 GLO1 (0.62) KEAP1NFE2L2IDO1MEN1KMT2A
SCHEMBL17737767 0.82 IDO1 (0.67) IDO1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL17737675 0.81 IDO1 (0.63) IDO1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL19852954 0.80 IDO1 (0.62) KEAP1NFE2L2IDO1MEN1KMT2A
SCHEMBL17737441 0.80 IDO1 (0.62) KEAP1IDO1MEN1KMT2ALMNA
SCHEMBL19852956 0.79 RECQL (0.69) IDO1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL17737365 0.78 IDO1 (0.63) IDO1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL15452718 0.78 IDO1 (0.62) KEAP1NFE2L2IDO1MEN1KMT2A
SCHEMBL17737362 0.78 IDO1 (0.62) IDO1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 — — US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 — — US disclosed
WO-2016071283-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 KEAP1 1682/4885NFE2L2 1629/4885IDO1 3/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 KEAP1 1682/4885NFE2L2 1629/4885IDO1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback